systems biology

Agastiya Biotech is a next-generation oncology company leveraging systems biology, immunotherapy, and quantum biophysics to develop cancer treatments. Its lead molecule, AB001, is a first-in-class, tumor-agnostic, orally available small molecule therapeutic. Following a Phase I trial with 33 patients across advanced metastatic cancers, Phase II trials are underway across multiple cancer types including lung, pancreas, and oral cancers. The company was founded by Dr. Baskaran Pillai and is headquartered in Carlsbad, CA.

Artificial intelligenceclinical trialsimmunotherapymolecular discoveryquantum biophysics

Athos Therapeutics Inc. is a clinical stage biotechnology company pioneering the development of artificial intelligence-based Precision Therapeutics for patients with Inflammatory Bowel Disease and other inflammatory diseases. It has developed a drug discovery and development platform that integrates medicinal chemistry and systems biology through machine learning to identify and develop novel drugs for patients with autoimmune and chronic inflammatory diseases.

computational medicinal chemistrydrug discovery and developmentmachine learningmedicinal chemistrysmall molecule synthesis

Emtherapro provides a next generation precision medicine enablement solution for neurodegenerative diseases, empowering biotech, life sciences and pharmaceutical companies to develop diagnostics and therapies. Anchored in proteomics, it integrates clinical, pathological, genetic and other omics data to advance biomarker discovery and validation for risk profiling, diagnosis, monitoring, prognosis and safety.

AIbiomarker identification and validationdrug engagement and dosage optimizationmachine learningMoA analysisomics data integrationparticipant screeningpre-clinical optimizationproteomicstarget identification and validation

Evimero is a life sciences company that combines systems biology, metaproteomics, and causal AI to transform biological complexity into actionable decisions. It develops next-generation biological intelligence platforms connecting molecular activity to real-world outcomes in health, performance, and disease, with applications across readiness optimization, diagnostics, biosurveillance, medical countermeasures, precision nutrition, and human performance for defense and commercial environments.

causal AImachine learningmetaproteomicsmulti-omics data analysis

Fulcrum Neuroscience develops a proprietary mathematical model of brain metabolism and a homeostasis-first, mechanism-first modeling platform for AI drug discovery in neurodegeneration. The platform generates virtual populations of tens of millions of discrete trajectories and has produced a unified hypothesis of Alzheimer's Disease implicating cholesterol debris processing upstream of amyloid and tau. The company is developing proprietary Alzheimer's therapeutics and biomarkers and assists partners by modeling disease progression, therapeutic effects, b

AI softwarebiomarker developmentcausal homeostatic modelingclinical trial modelingdifferential equation modeling across molecular, cellular, tissue and population scalesquantitative systems pharmacologyvirtual population generation